Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The PROTAC gold rush.

Literature DB >> 34907403

The PROTAC gold rush.

Ken Garber¹.
1. , Ann Arbor, Michigan, USA.

Abstract

Entities: Chemical

Mesh：

Substances：

Year: 2022 PMID： 34907403 DOI： 10.1038/s41587-021-01173-2

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

Keyword Cloud
Cited

× No keyword cloud information.

15 in total

1. PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.

Authors: Xin Han; Wenyi Wei; Yi Sun
Journal: Acta Mater Med Date: 2022-05-31

Review 2. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors: Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal: J Hematol Oncol Date: 2022-10-08 Impact factor: 23.168

Review 3. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.

Authors: Jyotsana Madan; Vijay Kamal Ahuja; Kamal Dua; Susanta Samajdar; Murali Ramchandra; Sanjeev Giri
Journal: BioDrugs Date: 2022-09-13 Impact factor: 7.744

Review 4. Major Advances in Emerging Degrader Technologies.

Authors: Hang Luo; Li Wu; Yujian He; Chong Qin; Xinjing Tang
Journal: Front Cell Dev Biol Date: 2022-06-22

Review 5. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.

Authors: Chao Wang; Yujing Zhang; Tingting Zhang; Lingyu Shi; Zhongmin Geng; Dongming Xing
Journal: J Enzyme Inhib Med Chem Date: 2022-12 Impact factor: 5.756

The PROTAC gold rush.

1. PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.

Review 2. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Review 3. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.

Review 4. Major Advances in Emerging Degrader Technologies.

Review 5. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges.

6. Direct-to-Biology Accelerates PROTAC Synthesis and the Evaluation of Linker Effects on Permeability and Degradation.

Review 7. Metabolism and Endocrine Disorders: What Wnt Wrong?

Review 8. Overcoming Cancer Drug Resistance Utilizing PROTAC Technology.

Review 9. Targeted protein degradation: mechanisms, strategies and application.

Review 10. Recent Approaches to the Identification of Novel Microtubule-Targeting Agents.